FDA approves Regeneron’s Pasatru for rare bone disorder FOP
First publishedAug 19, 18:04 UTC
Last updatedAug 19, 21:13 UTC · 9m ago
1 outlet
Investing.com · Company News
1 outlets over time — hover a bar for its window & outletslast updated
Answer
FDA approves Regeneron’s Pasatru for rare bone disorder FOP.
Reported by 1 outlet — Investing.com · Company News. See all sources ↓
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
In brief
- What's the story?
- FDA approves Regeneron’s Pasatru for rare bone disorder FOP.
- How widely is it covered?
- 1 outlet, average source rating 5.0/10.
- When was it last updated?
- 9m ago.
Different angles across outlets
Coverage map
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
FDA approves Regeneron’s Pasatru for rare bone disorder FOP
Sources1TypeCoverage
Related in the knowledge graph
Sources (1)
Avg source rating 5.0/10Processing cluster
A1A2A3B1B2B3